Rabbit Polyclonal RUNX2 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 15 publications.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
ICC | WB | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Rat | Predicted | Predicted |
Chimpanzee | Predicted | Predicted |
Chinese hamster | Predicted | Predicted |
Gorilla | Predicted | Predicted |
Macaque monkey | Predicted | Predicted |
Orangutan | Predicted | Predicted |
Rabbit | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Rabbit, Chimpanzee, Macaque monkey, Gorilla, Chinese hamster, Orangutan | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Rabbit, Chimpanzee, Macaque monkey, Gorilla, Chinese hamster, Orangutan | Dilution info - | Notes - |
Select an associated product type
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28703881, PubMed:28738062). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.
AML3, CBFA1, OSF2, PEBP2A, RUNX2, Runt-related transcription factor 2, Acute myeloid leukemia 3 protein, Core-binding factor subunit alpha-1, Oncogene AML-3, Osteoblast-specific transcription factor 2, Polyomavirus enhancer-binding protein 2 alpha A subunit, SL3-3 enhancer factor 1 alpha A subunit, SL3/AKV core-binding factor alpha A subunit, CBF-alpha-1, OSF-2, PEA2-alpha A, PEBP2-alpha A
Rabbit Polyclonal RUNX2 antibody. Suitable for ICC, WB and reacts with Human samples. Cited in 15 publications.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
RUNX2 also known as core-binding factor subunit alpha-1 (CBFA1) is a transcription factor with a molecular weight of approximately 56 kDa. It plays a pivotal role in regulating osteoblast differentiation and skeletal morphogenesis. This protein resides mainly in the nucleus and shows a high expression in bone tissue. RUNX2 binds to DNA sequences to control transcription of genes essential for bone development and maturation. The protein also possesses a Runt-homology domain enabling it to attach to specific DNA sequences.
This protein orchestrates bone formation by influencing the expression of genes involved in osteoblast differentiation. RUNX2 operates as part of the larger transcriptional complex that includes other proteins that modulate its activity. It maintains bone homeostasis by regulating the expression of osteogenic markers including bone sialoprotein and osteocalcin. The ability of RUNX2 to drive osteoblast lineage commitment highlights its importance in skeletal health and development.
RUNX2 shows significant involvement in both the Wnt signaling and TGF-beta signaling pathways. Within the Wnt signaling pathway RUNX2 interacts with beta-catenin to facilitate osteoblastogenesis and support bone matrix deposition. In the TGF-beta signaling pathway RUNX2 modulates Smad-dependent transcriptional activity important for extracellular matrix production and bone remodeling. These interactions illustrate RUNX2's central role in mediating bone development and maintenance.
RUNX2 mutations and dysregulation link to cleidocranial dysplasia a condition characterized by delayed closure of sutures in the skull and other skeletal anomalies. Additionally RUNX2 is related to osteosarcoma a type of bone cancer where its abnormal expression often contributes to tumor progression. In these contexts RUNX2 interacts with proteins like p53 an important regulator of cell cycle highlighting its influence on tumor suppressor networks and osteogenic pathways.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab114133 staining RUNX2 in U2OS cells. The cells were fixed with 4% paraformaldehyde (10 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab114133 at 5µg/ml and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).
Image was acquired with a confocal microscope (Leica-Microsystems TCS SP8) and a single confocal section is shown.
The predicted molecular weight of RUNX2 is 56 kDa (SwissProt), however we expect to observe a banding pattern around 65 kDa. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.
This antibody was raised against an immunogen that is predicted to recognize isoforms 1,2 and 3 of RUNX2. The predicted molecular weights of isoforms 1,2 and 3 are 56, 55 and 54 kDa respectively.
All lanes: Western blot - Anti-RUNX2 antibody (ab114133) at 1 µg/mL
All lanes: Saos 2 (Human epithelial-like osteosarcoma cell line) Whole Cell Lysate at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (Goat Anti-Rabbit IgG H&L (HRP) preadsorbed ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 57 kDa
Observed band size: 64 kDa, 65 kDa
Exposure time: 1min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com